Travere Therapeutics (TVTX) Scheduled to Post Quarterly Earnings on Monday

Travere Therapeutics (NASDAQ:TVTX) will announce its earnings results after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($0.98) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.11. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. The firm had revenue of $45.06 million for the quarter, compared to the consensus estimate of $41.25 million. On average, analysts expect Travere Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Travere Therapeutics Stock Up 1.6 %

Shares of NASDAQ:TVTX opened at $6.26 on Friday. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $19.54. The company has a quick ratio of 3.41, a current ratio of 3.47 and a debt-to-equity ratio of 1.88. The business’s 50-day moving average is $7.07 and its 200 day moving average is $7.60.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on TVTX shares. Wedbush reaffirmed an “outperform” rating and issued a $13.00 price target on shares of Travere Therapeutics in a report on Wednesday, April 17th. Guggenheim reissued a “neutral” rating on shares of Travere Therapeutics in a research note on Wednesday, March 27th. Piper Sandler boosted their price target on Travere Therapeutics from $10.00 to $11.00 and gave the stock a “neutral” rating in a research report on Thursday, January 18th. HC Wainwright raised their target price on shares of Travere Therapeutics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Wells Fargo & Company boosted their price target on shares of Travere Therapeutics from $8.00 to $9.00 and gave the company an “equal weight” rating in a research report on Friday, February 16th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $18.00.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.